Trends in BRCA testing and socioeconomic deprivation.
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
26
08
2018
accepted:
06
04
2019
revised:
19
03
2019
pubmed:
6
5
2019
medline:
13
6
2020
entrez:
5
5
2019
Statut:
ppublish
Résumé
BRCA testing received much publicity following Angelina Jolie's editorial "My Medical Choice" in May 2013 and updated NICE clinical guidance (CG164) in June 2013. We assessed the effect of these two concurrent events on BRCA testing in one UK catchment area and relate this to socioeconomic deprivation. A database of 1393 patients who received BRCA testing was collated. This included individuals with breast/ovarian cancer, and those unaffected by cancer, where a relative has a ≥10% probability of carrying a BRCA variant which affects function. A segmented regression was conducted to estimate changes in testing. To examine the relative distribution of testing by deprivation, the deprivation status of patients who received testing was examined. Between April 2010 and March 2017, testing increased 11-fold and there was an 84% increase (P = 0.006) in BRCA1/2 testing in the month following both publications. In the pre-publication period, there was no statistically significant difference in testing between advantaged and disadvantaged areas (OR 1.21, 95% CI 0.99-1.48; P = 0.06). In the post-publication period helped by a larger sample size, the difference was statistically significant (OR 1.18, 95% CI 1.08-1.29; P = 0.0002) and of a similar magnitude to the pre-publication period. Testing increased following Jolie's editorial and NICE guidance update. However, further research is needed to examine differences in testing by the deprivation group which adjusts for confounders.
Identifiants
pubmed: 31053786
doi: 10.1038/s41431-019-0424-3
pii: 10.1038/s41431-019-0424-3
pmc: PMC6777468
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1351-1360Subventions
Organisme : Medical Research Council
ID : MR/L006758/1
Pays : United Kingdom
Organisme : DH | National Institute for Health Research (NIHR)
ID : CLAHRC NWC 045
Pays : International
Références
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403. https://doi.org/10.1016/j.ejca.2012.12.027
doi: 10.1016/j.ejca.2012.12.027
pubmed: 23485231
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52–32. https://doi.org/10.3322/caac.21203
doi: 10.3322/caac.21203
pubmed: 24114568
Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol. 2013;129:258–64. https://doi.org/10.1016/j.ygyno.2012.12.016
doi: 10.1016/j.ygyno.2012.12.016
pubmed: 23266352
Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–10. BMC Med. 2015;13:1–10. https://doi.org/10.1186/s12916-015-0405-5
doi: 10.1186/s12916-015-0405-5
Rosenthal ET, Evans B, Kidd J, Brown K, Gorringe H, van Orman M, et al. Increased identification of candidates for high-risk breast cancer screening through expanded genetic testing. J Am Coll Radiol. 2017;14:561–8. https://doi.org/10.1016/j.jacr.2016.10.003
doi: 10.1016/j.jacr.2016.10.003
pubmed: 28011157
Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–57. https://doi.org/10.1200/JCO.2012.43.1882
doi: 10.1200/JCO.2012.43.1882
pubmed: 23569316
pmcid: 3641696
Cavanagh H, Rogers KMA. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015;13:1–7. https://doi.org/10.1186/s13053-015-0038-x
doi: 10.1186/s13053-015-0038-x
Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? Eur J Hum Genet. 2016;24(S1):S3–S9. https://doi.org/10.1038/ejhg.2016.93
doi: 10.1038/ejhg.2016.93
pubmed: 27514841
pmcid: 5141575
Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374:454–68. https://doi.org/10.1056/NEJMra1503523
doi: 10.1056/NEJMra1503523
pubmed: 26840135
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;27(Supplement 5):v103–v110. https://doi.org/10.1093/annonc/mdw327
doi: 10.1093/annonc/mdw327
pubmed: 27664246
Manchanda R, Patel S, Gordeev VS, Antoniou AC, Smith S, Lee A, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. JNCI J Natl Cancer Inst. 2018;110:1–12. https://doi.org/10.1093/jnci/djx265
doi: 10.1093/jnci/djx265
Jolie A. My Medical Choice. The New York Times. 2013. http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html .
Staudigl C, Pfeiler G, Hrauda K, Renz R, Berger A, Lichtenschopf R, et al. Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the “Angelina Jolie Effect.”. BMC Cancer. 2016;16:436 https://doi.org/10.1186/s12885-016-2472-1
doi: 10.1186/s12885-016-2472-1
pubmed: 27391110
pmcid: 4938920
Evans DGR, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 2014;16:442 https://doi.org/10.1186/s13058-014-0442-6
doi: 10.1186/s13058-014-0442-6
pubmed: 25510853
pmcid: 4303122
Desai S, Jena AB. Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie’s New York Times editorial. Bmj. 2016:i6357. https://doi.org/10.1136/bmj.i6357
NICE. Familial breast cancer: the classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Clinical Guideline 164. London; 2013. http://guidance.nice.org.uk/CG164 .
Exarchakou A, Rachet B, Belot A, Maringe C, Coleman MP. Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996-2013: population based study. Bmj. 2018:k764. https://doi.org/10.1136/bmj.k764
Murray C, Lopez A. Global mortality, disability and the contribution of risk factors: global burden of disease study. Lancet. 1997;349(1436–42.).
Newton JN, Briggs ADM, Murray CJL, Dicker D, Foreman KJ, Wang H, et al. Changes in health in England, with analysis by English regions and areas of deprivation, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:2257–74. https://doi.org/10.1016/S0140-6736(15)00195-6
doi: 10.1016/S0140-6736(15)00195-6
pubmed: 26382241
pmcid: 4672153
PHE. The NHS atlas of variation in diagnostic services: reducing unwarranted variation to increase value and improve quality. London; 2013. www.rightcare.nhs.uk .
Kroese M, Deller J, Dew C, Murrary P, Salah S, Danks R, et al. Genetic test activity in England & Scotland. NHS UKGTN.1- 73. 2018. https://ukgtn.nhs.uk/fileadmin/uploads/ukgtn/Documents/Resources/Library/Reports_Guidelines/NHS_Directory_of_Genetic_Testing/UKGTN_Genetic_test_activity_final_July_2018
Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for Reporting Implementation Studies (StaRI): explanation and elaboration document. BMJ Open. 2017;7:e013318 https://doi.org/10.1136/bmjopen-2016-013318
doi: 10.1136/bmjopen-2016-013318
pubmed: 28373250
pmcid: 5387970
National Institute for Health and Care Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. Clinical guideline 2004;14. http://guidance.nice.org.uk/CG14 .
National Institute for Health and Care Excellence. Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. Clinical guideline 2006;41. http://guidance.nice.org.uk/CG41 .
Evans DG, Graham J, O’Connell S, Arnold S, Fitzsimmons D. Familial breast cancer: summary of updated NICE guidance. BMJ . 2013;346:4–7. https://doi.org/10.1136/bmj.f3829
doi: 10.1136/bmj.f3829
Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. BMJ. 2001;322:1052–6. https://doi.org/10.1136/bmj.322.7293.1052
doi: 10.1136/bmj.322.7293.1052
pubmed: 11325775
pmcid: 1120190
Marmot M. Fair Society Healthy Lives (The Marmot Review). London; 2010. https://doi.org/10.1136/bmj.c1191
Eberth B, Olajide D, Craig P, Ludbrook A. Smoking-related disease risk, area deprivation and health behaviours. J Public Heal (U Kingd). 2014;36:72–80. https://doi.org/10.1093/pubmed/fdt031
doi: 10.1093/pubmed/fdt031
Department for Communities and Local Government. English indices of deprivation 2015. https://www.gov.uk/government/statistics/english-indices-ofdeprivation-2015 . (Accessed 2 May 2019).
Office for National Statistics. Lower layer super output area population estimates. 2018. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/lowersuperoutputareamidyearpopulationestimates .
Department of Health. The NHS Constitution for England. 2015. https://www.gov.uk/ government/publications/the-nhs-constitution-for-england/the-nhsconstitution-forengland . (Accessed 2 May 2019).
Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46:348–55. https://doi.org/10.1093/ije/dyw098
doi: 10.1093/ije/dyw098
pubmed: 27283160
Wagner A, Soumerai S, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x
doi: 10.1046/j.1365-2710.2002.00430.x
pubmed: 12174032
Zhang F, Wagner AK, Soumerai SB, Ross-degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol. 2013;62:1–11. https://doi.org/10.1016/j.jclinepi.2008.08.007.Methods
doi: 10.1016/j.jclinepi.2008.08.007.Methods
R: A language and environment for statistical computing. Vienna: Development Core Team; 2008.
George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:29506 https://doi.org/10.1038/srep29506
doi: 10.1038/srep29506
pubmed: 27406733
pmcid: 4942815
Kentwell M, Dow E, Antill Y, Wrede CD, Mcnally O, Higgs E, et al. Gynecologic oncology mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017;145:1–7. https://doi.org/10.1016/j.ygyno.2017.01.030
doi: 10.1016/j.ygyno.2017.01.030
Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet. 2016;2013:1–7. https://doi.org/10.1136/jmedgenet-2016-103902
doi: 10.1136/jmedgenet-2016-103902
Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33. https://doi.org/10.1056/NEJMoa1706450
doi: 10.1056/NEJMoa1706450
pubmed: 28578601
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61. https://doi.org/10.1016/S1470-2045(14)70228-1
doi: 10.1016/S1470-2045(14)70228-1
pubmed: 24882434
Wright S, Porteous M, Stirling D, Lawton J, Young O, Gourley C, et al. Patients’ views of treatment-focused genetic testing (TFGT): some lessons for the mainstreaming of BRCA1 and BRCA2 testing. J Genet Couns. 2018:1–14. https://doi.org/10.1007/s10897-018-0261-5
NICE. Final appraisal determination olaparib for maintenance treatment of relapsed, platinum-sensitive, brca mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy. 2015. (Technology appraisal guidance 381). http://nice.org.uk/guidance/ta381
Levy DE, Byfield SD, Comstock CB, Judy E, Syngal S, Crown WH, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13:349–55. https://doi.org/10.1097/GIM.0b013e3182091ba4.Underutilization
doi: 10.1097/GIM.0b013e3182091ba4.Underutilization
pubmed: 21358336
pmcid: 3604880
Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen L. May. Disparities in genetics assessment for women with ovarian cancer: can we do better?. Gynecol Oncol. 2018;149:84–88. https://doi.org/10.1016/j.ygyno.2017.10.034
doi: 10.1016/j.ygyno.2017.10.034
pubmed: 29605055
Yusuf R, Rogith D, Hovick S, Peterson S, Burton-Chase A, Fellman D, et al. Attitudes towards molecular testing for personalized cancer therapy. Cancer. 2015;121:243–50. https://doi.org/10.1002/cncr.28966.Attitudes
doi: 10.1002/cncr.28966.Attitudes
pubmed: 25209923
Burns C, Mcgaughran J, Davis A, Semsarian C, Ingles J. Factors influencing uptake of familial long QT syndrome genetic testing. Am J Med Genet Part A. 2016;170:418–25. https://doi.org/10.1002/ajmg.a.37455
doi: 10.1002/ajmg.a.37455
Kilambi V, Johnson FR, González JM, Mohamed AF. Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. Value Heal. 2014;17:838–45. https://doi.org/10.1016/j.jval.2014.09.001
doi: 10.1016/j.jval.2014.09.001
Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M. The spectrum of CFTR variants in nonwhite cystic fibrosis patients: implications for molecular diagnostic testing. J Mol Diagn. 2016;18:39–50. https://doi.org/10.1016/j.jmoldx.2015.07.005
doi: 10.1016/j.jmoldx.2015.07.005
pubmed: 26708955
Smith CE, Fullerton SM, Dookeran KA, Hampel H, Tin A, Maruthur NM, et al. Using genetic technologies to reduce, rather than widen, health disparities. Health Aff. 2016;35:1367–73. https://doi.org/10.1377/hlthaff.2015.1476
doi: 10.1377/hlthaff.2015.1476
Sweeny K, Ghane A, Legg AM, Huynh HP, Andrews SE. Predictors of genetic testing decisions: a systematic review and critique of the literature. J Genet Couns. 2014;23:263–88. https://doi.org/10.1007/s10897-014-9712-9
doi: 10.1007/s10897-014-9712-9
pubmed: 24719248
Borzekowski DLG, Guan Y, Smith KC, Erby LH, Roter DL. The Angelina effect: immediate reach, grasp, and impact of going public. Genet Med. 2014;16:516–21. https://doi.org/10.1038/gim.2013.181
doi: 10.1038/gim.2013.181
pubmed: 24357847
Roberts MC, Dusetzina SB. The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use. J Community Genet. 2017:141–6. https://doi.org/10.1007/s12687-017-0295-7
Jandoc R, Burden AM, Mamdani M, Lévesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations. J Clin Epidemiol. 2015;68:950–6. https://doi.org/10.1016/j.jclinepi.2014.12.018
doi: 10.1016/j.jclinepi.2014.12.018
pubmed: 25890805